The case for long-acting antipsychotic agents in the post-CATIE era. (Q36758680)

16 August 2017

1 reference

title

The case for long-acting antipsychotic agents in the post-CATIE era. (English)

1 reference

16 August 2017

Nasrallah HA

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Acta Psychiatrica Scandinavica

16 August 2017

published in

1 reference

16 August 2017

volume

115

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

260-267

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Tolerability of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Qualitative assessment of brain morphology in acute and chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Atypical neuroleptics stimulate neurogenesis in adult rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00982.X

10.1111/J.1600-0447.2006.00982.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference